Current oncology最新文献

{"title":"Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).","authors":"Tobias Berg, Brittany Salter, Michael Radford, He Tian Tony Chen, Brian Leber","doi":"10.3390/curroncol32060319","DOIUrl":"10.3390/curroncol32060319","url":null,"abstract":"<p><p>Allogeneic hematopoietic cell transplantation (alloHCT) is the sole curative therapy for myelodysplastic syndrome (MDS). While alloHCT clearly confers a significant survival advantage in high-risk MDS, it is less clear how the disease burden and impact of conditioning intensity impact survival. This review addresses critical issues surrounding this topic, emphasizing the unique cell biology of MDS and the evolving concepts of conditioning intensity compared to other diseases, including acute myeloid leukemia (AML). The review is structured around three interconnected themes. First, it clarifies the varying interpretations of conditioning intensity. Second, it examines the interplay between disease burden at transplant and conditioning intensity in determining outcomes, including a comparative analysis with acute myeloid leukemia (AML) to highlight similarities and differences. Third, it explores the relationship between conditioning regimen intensity and immune reconstitution, particularly focusing on the graft-versus-tumor (GvT) effect and its potential modulation by conditioning intensity. Understanding the stem cell target of conditioning regimens is emphasized, as the persistence of the underlying MDS stem cell necessitates a thorough understanding of this concept for improved therapeutic strategies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?","authors":"Pilar Lloret-Madrid, Pedro Chorão, Manuel Guerreiro, Pau Montesinos","doi":"10.3390/curroncol32060322","DOIUrl":"10.3390/curroncol32060322","url":null,"abstract":"<p><p><b>Background</b>: Patients with refractory and relapsed acute myeloid leukemia (R/R AML) face a dismal prognosis. CAR-T therapy has emerged as a potential treatment option. This study assesses the available clinical evidence on CAR-T in R/R AML, focusing on safety and efficacy outcomes. <b>Methods</b>: We included studies on CAR-T therapy for R/R AML published from June 2014 to January 2025. Data on patient and disease characteristics, CAR-T constructs, response rates, post-CAR-T allogeneic HSCT (allo-HSCT), and safety outcomes were analyzed. <b>Results</b>: Twenty-five CAR-T clinical trials involving 296 patients were identified. The most frequently targeted antigens were CD33, CD123, and CLL-1, while CD7, CD19, NKG2D, and CD38 were also explored. Responses were heterogeneous and often short-lived when not consolidated with allo-HSCT. Cytokine release syndrome and neurotoxicity were generally low grade and manageable. Prolonged and severe myelosuppression was a frequent limiting toxicity, often requiring allo-HSCT to restore hematopoiesis. Disease progression was the leading cause of death, followed by infections. <b>Conclusions</b>: CAR-T cell therapy may represent a feasible therapeutic strategy, particularly as bridging to allo-HSCT to mitigate myelotoxicity and improve long-term outcomes. Nevertheless, it remains in the early stages of development and faces significant efficacy and safety challenges that must be addressed in future trials to enable the expansion of this promising therapeutic approach for a population with high unmet medical needs.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Management of Extra-Abdominal Desmoid Fibromatosis: A Retrospective Analysis of Treatments, Outcomes and Recurrence Patterns.","authors":"Vidhi Saraf, Hariharan Triplicane Dwarakanathan, Al-Muaayad Al-Abri, Ioanna Nixon, Sarah Vaughan, Ashish Mahendra, Sanjay Gupta","doi":"10.3390/curroncol32060320","DOIUrl":"10.3390/curroncol32060320","url":null,"abstract":"<p><p><b>Background:</b> Desmoid fibromatosis (DF) is a rare, locally aggressive soft tissue tumour with unpredictable clinical behaviour. Historically, treatment has involved surgery; however, contemporary guidelines, such as those from the Desmoid Tumour Working Group, advocate active surveillance. This article reviews current perspectives on DF, focusing on epidemiology, pathogenesis, treatment strategies, emerging research directions and cost effectiveness based on our experience at the West of Scotland Musculoskeletal Oncology Service, Glasgow Royal Infirmary (GRI). <b>Methodology:</b> We reviewed 101 patients diagnosed with desmoid fibromatosis between 2010 and 2024. A review of patient records was conducted to gather information on demographics, date of diagnosis, prior treatment, treatment initiation, intervention types, imaging intervals, follow-up duration, recurrence rate for surgery and other intervention, and discharge timelines. All data was systematically organized and analyzed to assess our outcomes. <b>Results:</b> Out of 101 patients with DF in the study, 66% were females. The most common site of primary tumour was lower extremity (39.6%) followed by near equal distribution in upper extremity and trunk. Out of the total cases, 72 (71.2%) were successfully managed with active surveillance involving serial imaging and clinical reviews in accordance with European guidelines. A total of 22 patients (21%) received treatment: 10 underwent surgery alone, 2 had surgery combined with radiotherapy, 8 received only radiotherapy, 1 was treated with hormonal therapy and 1 participated in a trial with Nirogacestat. Of the seven remaining patients, six had unplanned surgery outside followed by active surveillance at GRI. One patient was on alternative treatment modality, homeopathy. The average number of MRI scans per patient was 3.11, with many patients requiring significantly more imaging. MRI surveillance varies significantly in desmoid tumours due to their heterogeneous behaviour. Active or symptomatic tumours often require more frequent scans (every 3-6 months), while stable cases may need only imaging annually or just clinical monitoring. Recurrence was noted in eight patients, all of which were related to prior surgery. The total combined cost of imaging and appointments exceeds £6500 per patient in active surveillance. <b>Conclusions:</b> We conclude that most patients with desmoid fibromatosis in our cohort were effectively treated with active surveillance, consistent with current European guidelines. Surgical management of desmoid fibromatosis in our cohort is historic and has shown a significant recurrence risk. Our study proposes a revised follow-up protocol that significantly reduces costs without compromising on patient care. We suggest a two-year surveillance period for stable disease with patient-initiated return to reduce unnecessary clinic visits, imaging and healthcare costs.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Deep Learning-Based Auto-Contouring Software Achieve Accurate Pelvic Volume Delineation in Volumetric Image-Guided Radiotherapy for Prostate Cancer? A Preliminary Multicentric Analysis.","authors":"Cristiano Grossi, Fernando Munoz, Ilaria Bonavero, Eulalie Joelle Tondji Ngassam, Elisabetta Garibaldi, Claudia Airaldi, Elena Celia, Daniela Nassisi, Andrea Brignoli, Elisabetta Trino, Lavinia Bianco, Silvia Leardi, Diego Bongiovanni, Chiara Valero, Maria Grazia Ruo Redda","doi":"10.3390/curroncol32060321","DOIUrl":"10.3390/curroncol32060321","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) is a mainstay treatment for prostate cancer (PC). Accurate delineation of organs at risk (OARs) is crucial for optimizing the therapeutic window by minimizing side effects. Manual segmentation is time-consuming and prone to inter-operator variability. This study investigates the performance of Limbus^® Contour^® (LC), a deep learning-based auto-contouring software, in delineating pelvic structures in PC patients.</p><p><strong>Methods: </strong>We evaluated LC's performance on key structures (bowel bag, bladder, rectum, sigmoid colon, and pelvic lymph nodes) in 52 patients. We compared auto-contoured structures with those manually delineated by radiation oncologists using different metrics.</p><p><strong>Results: </strong>LC achieved good agreement for the bladder (median Dice: 0.95) and rectum (median Dice: 0.83). However, limitations were observed for the bowel bag (median Dice: 0.64) and sigmoid colon (median Dice: 0.6), with inclusion of irrelevant structures. While the median Dice for pelvic lymph nodes was acceptable (0.73), the software lacked sub-regional differentiation, limiting its applicability in certain other oncologic settings.</p><p><strong>Conclusions: </strong>LC shows promise for automating OAR delineation in prostate radiotherapy, particularly for the bladder and rectum. Improvements are needed for bowel bag, sigmoid colon, and lymph node sub-regionalization. Further validation with a broader and larger patient cohort is recommended to assess generalizability.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Classification Guides Fertility-Sparing Treatment for Endometrial Cancer and Atypical Hyperplasia Patients.","authors":"Yiqin Wang, Linlin Bo, Xiaowei Fan, Nan Kang, Xiaobo Zhang, Li Tian, Rong Zhou, Jianliu Wang","doi":"10.3390/curroncol32060317","DOIUrl":"10.3390/curroncol32060317","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of this study was to investigate the significance of molecular classification in guiding treatment decisions for patients with endometrial cancer (EC) or atypical hyperplasia (AH) undergoing fertility-sparing treatment (FST), particularly for those with non-NSMP subtypes.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study involving EC/AH patients undergoing FST and molecular classification using next-generation sequencing at Peking University People's Hospital between June 2020 and September 2023.</p><p><strong>Results: </strong>A total of 118 EC/AH patients were included, including 92 cases with NSMP, 11 with MMRd, 11 with <i>POLE</i>mut, and 4 with p53abn. (1) Of the 11 patients with MMRd, 6 achieved a complete response (CR) with 1 case receiving progestin, 3 cases showed insensitivity to the initial progestin before transitioning to a combined regimen of progestin and a PD-1 inhibitor, and 2 cases initially received progestin plus a PD-1 inhibitor. There were no significant differences in the cumulative CR rates between the MMRd and NSMP subgroups but a trend of a lower relapse-free-survival (RFS) rate for the MMRd subgroup (<i>p</i> = 0.074). (2) Of the 11 cases with <i>POLE</i>mut, 10 achieved CR but 4 relapsed. There was also a trend for a lower RFS rate in the <i>POLE</i>mut patients (<i>p</i> = 0.069) compared with the NSMP subgroup. (3) Three of the four patients with p53mut achieved CR after treatment with the GnRHa plus LNG-IUS regimen.</p><p><strong>Conclusion: </strong>The selection of appropriate regimens may improve FST outcomes in EC/AH patients with molecular classification of non-NSMP subtypes. Immunotherapy is an effective fertility-preserving approach for patients with MMRd.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Unmet Needs of Palliative Care Among Young and Middle-Aged Patients with Advanced Cancer: A Qualitative Study.","authors":"Renhui Wen, Xinyi Liu, Yu Luo","doi":"10.3390/curroncol32060314","DOIUrl":"10.3390/curroncol32060314","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the unmet palliative care needs among young and middle-aged (YMA) Chinese patients with advanced cancer.</p><p><strong>Methods: </strong>We used the principle of maximum difference. A total of 16 YMA patients with advanced cancer from cancer hospital were recruited. Semi-structured, in-depth, and face-to-face interviews were conducted from 28 August 2023 to 23 October 2023. The recorded audio of each interview was typed into Word software with each personal code. The interview transcripts were coded using the method of inductive content analysis.</p><p><strong>Results: </strong>Four themes and 14 sub-themes were identified in participants' descriptions of care needs: (1) symptom management needs: need for pain relief, need for anti-emetics, and need for aid in managing fatigue; (2) psychological support needs: help reducing fear of pain, help achieving a better death, and help with parents' negative reactions; (3) social support needs: taking care of children, emotional support from family members, consultation and emotional support from other cancer patients, and company and guidance of healthcare personnel; (4) information needs: better understanding of disease trajectory and future care needs, better access to palliative care information, and more participation in medical decision-making.</p><p><strong>Conclusions: </strong>According to the results of this study, the unmet palliative care needs of YMA patients with advanced cancer are diverse, but they have not been fully recognized and met. Therefore, medical staff should develop effective management strategies and explore patients' needs in an all-around way. Future studies will further develop the scale of unmet needs for palliative care to accurately identify needs and improve patients' quality of life.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling Racial Disparities in Papillary Thyroid Cancer: A Comparative Bulk RNA-Sequencing Gene Expression Analysis.","authors":"Luiza Barseghyan, Samuel Chan, Celina R Yamauchi, Andrea Shields, Mia C Perez, Alfred A Simental, Salma Khan","doi":"10.3390/curroncol32060315","DOIUrl":"10.3390/curroncol32060315","url":null,"abstract":"<p><p>Papillary thyroid cancer (PTC) is the most common thyroid malignancy, with significant racial/ethnic disparities in incidence and survival. Asians have the highest incidence, and recurrence, while African Americans experience the lowest survival rates, suggesting contributions from genetic, environmental, and healthcare-related factors. While socioeconomic disparities play a role, emerging evidence highlights genetic and molecular mechanisms underlying these differences. This study examines differentially expressed genes (DEGs) to identify potential molecular drivers of PTC disparities. Bulk RNA-sequencing (RNA-seq) data from 20 PTC tumors (5 White, 5 African American, 5 Hispanic, and 5 Asian) were analyzed using the UseGalaxy platform. Preprocessing included quality control, adapter trimming, and genome alignment. Differential expression analysis identified genes with <i>p</i> < 0.01 and fold change ≥ 2.5. Volcano plots visualized significant DEGs. Gene Set Enrichment Analysis (GSEA) via eVITTA identified enriched pathways. TCGA data analysis validated racial/ethnic differences in gene expression. Ethnic groups exhibited distinct gene expression profiles. GSEA revealed differences in cell proliferation, immune regulation, and thyroid hormone metabolism. African Americans showed immune suppression and reduced tumor suppressor activity, while Asians exhibited enriched cell cycle and DNA repair pathways. Significant differences were confirmed in some of the genes in TCGA data analysis. This study identifies genetic factors contributing to racial disparities in PTC, emphasizing the need for further validation in larger cohorts and functional studies. Understanding these molecular differences may inform personalized treatment strategies and improve PTC outcomes across diverse populations.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Treatment Plan Modifications from Surgeons' Initial Recommendations to Multidisciplinary Tumor Board Consensus for Cancer Care in a Resource-Limited Setting.","authors":"Sajida Qureshi, Waqas Ahmad Abbasi, Hira Abdul Jalil, Raheel Ahmed, Mubashir Iqbal, Hanieya Saiyed, Hira Fatima Waseem, Najeeb Naimatullah, Syed Rashidul Amin, Muhammad Saeed Quraishy","doi":"10.3390/curroncol32060310","DOIUrl":"10.3390/curroncol32060310","url":null,"abstract":"<p><p>Multidisciplinary tumor boards (MTBs) are essential for optimizing cancer care through collaborative decision-making. However, the concordance between initial surgeons' recommendations and MTB outcomes, particularly in resource-limited settings, remains underexplored. This study evaluates the agreement between treatment plans proposed initially by surgeons and those finalized through MTB discussions conducted at the same stage of patient evaluation, with a focus on changes in treatment intent between curative and palliative care. A retrospective analysis of 216 patients discussed at bi-weekly MTB meetings between January 2021 and December 2023 at a tertiary care hospital was conducted. Statistical tests, including kappa statistics and concordance analysis were applied to assess the interrater agreement between surgeon-recommended and MTB-finalized decisions and to evaluate changes in treatment intent. A <i>p</i>-value < 0.05 was considered statistically significant. Strong concordance and significant perfect agreement were observed between curative versus palliative decisions of surgeons and MTBs, (Cohen's kappa = 0.89, <i>p</i> < 0.001). MTB recommendations were added to the surgeons' suggested plans in 38.4% (n = 83) of cases and replaced them entirely in 25.0% (n = 54) of cases. Shifts in treatment intent from curative to palliative or vice versa were infrequent (2.31%, n = 5), specifically in esophageal and stomach cancers. MTB decisions achieved a 100% implementation rate. This study underscores the critical role of MTBs in collaborative decision-making and their value as an essential tool for consistent, individualized, and evidence-based cancer care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacts of Hematopoietic Stem Cell Transplantation on Quality of Life and Behavioral Outcomes in Pediatric Patients with Leukemia and Thalassemia.","authors":"Aysun Kara Uzun, Sevilay Yıldız Akkuş, Ayça Koca Yozgat, Fadime Yüksel, Özlem Arman Bilir, Hüsniye Neşe Yaralı, Namık Yaşar Özbek","doi":"10.3390/curroncol32060311","DOIUrl":"10.3390/curroncol32060311","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the effects of allogeneic hematopoietic stem cell transplantation (HSCT) on quality of life and behavioral problems in children diagnosed with leukemia and β-thalassemia major, with a focus on post-transplant diagnosis-specific differences in psychosocial adjustment.</p><p><strong>Method: </strong>This study included 112 children (63 children with acute leukemia, 49 children with β-thalassemia major) aged 6-18 years, along with a control group of 30 healthy children within the same age range. The Pediatric Quality of Life Inventory (PedsQL) and the Child Behavior Checklist for Ages 6-18 (CBCL) were administered. Participants were categorized into five groups, and the outcomes were compared accordingly.</p><p><strong>Results: </strong>The emotional functioning subscale scores of the PedsQL were significantly lower in children with leukemia and those who had undergone HSCT for leukemia, when compared to children with thalassemia (<i>p</i> < 0.05). The social functioning subscale scores were also significantly lower in children with leukemia who underwent HSCT compared to those with thalassemia (<i>p</i> < 0.05). The CBCL internalizing scores were higher in children with leukemia and post-HSCT leukemia patients than in their healthy peers (<i>p</i> < 0.05). Over time, both diagnostic groups showed improvements, with total PedsQL scores increasing and total CBCL scores decreasing after HSCT.</p><p><strong>Conclusions: </strong>This study demonstrates that quality of life improved and behavioral problems diminished over time following HSCT. However, the psychosocial impact of HSCT varied depending on the underlying disease, with children diagnosed with leukemia being slightly more adversely affected. These findings suggest that interventions aimed at improving quality of life and addressing behavioral issues should be tailored to the specific diagnosis.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements.","authors":"Wei Xu, Qing Li, Bin Liang","doi":"10.3390/curroncol32060313","DOIUrl":"10.3390/curroncol32060313","url":null,"abstract":"<p><p>Intermediate- and advanced-stage hepatocellular carcinoma (HCC) continues to present significant therapeutic challenges. Hepatic artery infusion chemotherapy (HAIC), a well-established locoregional treatment for unresectable HCC, has recently demonstrated promising clinical outcomes both as monotherapy and in combination with systemic therapies. This comprehensive review examines recent clinical advances in HAIC for HCC, with particular emphasis on evolving treatment regimens and their therapeutic efficacy.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}